Business Context and Reporting Period
Company: Novavax, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: April 23, 2021
Event: Entry into a Material Definitive Agreement (Modification No. 7 to Project Agreement No. 01).
Key Financial Metrics
This filing reports a specific funding increase rather than comprehensive financial statements. Key figures include:
- Funding Increase: $147,349,805
- Total Funding Available: $1,747,689,328
- Counterparty: Advanced Technology International (ATI) on behalf of the Medical CBRN Defense Consortium (Operation Warp Speed).
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity for the period.
Material Changes
The primary material change is the execution of Modification No. 7 to the Project Agreement dated July 6, 2020. This modification increases the funding available for payment and allotted to the Project Agreement by approximately $147.3 million. The remainder of the Project Agreement remains unchanged.
Outlook, Risks, and Management Commentary
Management Commentary: The Company states that the modification increases funding available for the partnership formerly known as Operation Warp Speed (OWS), which involves the U.S. Department of Health and Human Services and the U.S. Department of Defense to accelerate COVID-19 vaccine development, manufacturing, and distribution.
Contingencies and Unusual Items: The full text of the Modification is not included in this report but will be filed as an exhibit to the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2021.
Investor Verification Checklist
- Verify the specific terms and conditions of Modification No. 7 in the upcoming Form 10-Q exhibit.
- Confirm the impact of the $147.3 million funding increase on the Company's cash position and burn rate in the next quarterly report.
- Review the status of the Project Agreement to ensure no other clauses were altered alongside the funding increase.